Global Anticoagulants Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027

“Global Anticoagulants Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2027” is a recent report generated by MarketResearch.biz, which offers in-depth insights, revenue details, and other vital information regarding the global anticoagulants market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global anticoagulants market report has been segmented on the basis of drug class, route of administration, application, and region.

Request Covid - 19 Impact

Introduction:

Anticoagulant is called as blood thinners. Anticoagulants are medicines that help to prevent blood clots. A blood clot is a seal created by the blood to stop bleeding from wounds. Anticoagulants work by interrupting the process in the formation of blood clots. It reduces the risk of embolization of blood clots to other vital organs such as the lungs and brain. There are several different types of anticoagulant drugs. Each type works at a different level on the blood coagulation pathway in body. Anticoagulant is administered via mouth or injection.

Market Dynamics:

Key factors expected to drive growth of the global anticoagulants market is increasing incidence of cardiovascular disease. In addition, increasing healthcare expenditure, growing elderly population, rising incidences of chronic disease, increasing prevalence rate of arterial and venous thrombosis are among some other factors expected to drive growth of the global anticoagulants market. However, string regulatory rule may hamper the growth of the global anticoagulants market to a certain extent. In addition, certain side effect and complications associated with the usage of oral anticoagulants is expected to hamper the growth of the target market.

Trends:

Major manufacturers are focus on carrying various R&D activates, in order to develop new innovative anticoagulants drugs. Government of various countries are funding the research and developing activities carried out by serval pharmaceutical companies. Established players are partnering with other local players, in order to enhance their product offerings as well as to expand global footprint. For instance: in 2013, Bayer and Janssen entered into clinical collaboration agreement, in order to phase 2 study of PRT4445 and XARELTO, that ae works by blocking the blood clotting enzyme factors in human body.

Regional Analysis:

The market in North America is expected to dominate the global anticoagulants market, owing to increasing incidences chronic diseases such as diabetes and strokes in countries in the region. According to national action plan for adverse drug event prevention, in 2017 US prevalence rate of   anticoagulants is approximately 2.6 Mn and is expected to reach 12 Mn by 20150. In contrast, the market in Asia Pacific is expected to be an emerging market for the global Anticoagulants market, and is expected to register highest CAGR in during the forecasted period, owing to growing demand for ideal therapeutics in the region. Moreover, the markets in Europe, Latin America and Middle East & Africa are expected to register moderate growth revenue over the forecast period.

GLOBAL ANTICOAGULANTS MARKET SEGMENTATION:

Segmentation by drug class:

• NOACs
  • Eliquis
  • Bevyxxa
  • Xarelto
  • Savaysa & lixiana
  • Pradaxa

• Heparin & LMWH
• Vitamin K Antagonist

Segmentation by route of administration:

• Oral anticoagulant
• Injectable anticoagulant

 Segmentation by application:

• Atrial fibrillation & heart attack
• Stroke
• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Others (include blood clots within venous and arterial catheters, blood clots during atrial fibrillation (AFIB) treatment, etc.)

 Segmentation by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Aspen Holdings
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company
• GlaxoSmithKline plc.
• Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
• Pfizer, Inc.
• Portola Pharmaceuticals, Inc.
• Sanofi S.A.